The C-Pulse Heart Assist System story is "still early with U.S. commercialization years away [but] feasibility trial data are encouraging, European approval is secured and the market opportunity is significant," Oppenheimer's Steven Lichtman says, initiating shares of Sunshine Heart (SSH +5.2%) at Outperform with an $11 price target. The new coverage was reported here yesterday and has the shares moving sharply higher in early trading. "The next major catalysts will be reimbursement notifications in Europe early in '14," Lichtman notes.
The C-Pulse Heart Assist System story is "still early with U.S. commercialization years away...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs